Fedratinib (Inrebic)

Abstract

Clinical evidence suggests that the JAK inhibitor Inrebic should be reimbursed as a treatment option for adults with myelofibrosis who cannot take or tolerate Jakavi. Inrebic cannot be prescribed to those who progress on Jakavi. There is insufficient evidence to justify a cost premium for Inrebic over other JAK inhibitors reimbursed for the treatment of myelofibrosis. If Inrebic is not reimbursed by public payers, best available therapy will be the only other treatment option for patients who cannot take Jakavi.